Grace Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 12, 2026, disclosing operational and regulatory developments related to its lead drug candidate GTx-104.

Key Highlights

  • Shares outstanding: As of November 11, 2026, Grace Therapeutics had 21,035,930 shares of common stock outstanding.
  • Lead candidate: GTx-104 is the company's lead drug candidate, targeting management of hypotension in patients with aneurysmal subarachnoid hemorrhage (aSAH), according to the filing.
  • FDA Complete Response Letter: The company disclosed it received a Complete Response Letter (CRL) from the FDA related to GTx-104 and is working to address the items cited in that letter.
  • Manufacturing compliance concerns: The filing states the company's current contract manufacturer must remediate deficiencies identified during a cGMP inspection cited in the FDA's CRL, and that the FDA will not approve the NDA while the facility remains in an unacceptable compliance status.
  • Second manufacturer in progress: A U.S.-based second contract manufacturer must complete technology transfer, manufacture three registration batches, and generate 12 months of stability data before it can support approval.
  • De-prioritized candidates: The company disclosed plans to maximize the value of GTx-102 and GTx-101 through potential licensing or sale.
  • Filer classification: Grace Therapeutics is classified as a non-accelerated filer and smaller reporting company.

GTx-104 Regulatory Status and Manufacturing Challenges at Grace Therapeutics

Grace Therapeutics, Inc. (NASDAQ:GRCE), headquartered at 103 Carnegie Center Suite 300, Princeton, New Jersey 08540, filed its Form 10-Q for the quarterly period ended September 30, 2026. The company describes itself as focused on rare and orphan diseases, applying proprietary formulations to existing pharmaceutical compounds with the goal of achieving enhanced efficacy and improved drug delivery.

The filing centers significantly on the regulatory path for GTx-104, an intravenous formulation of nimodipine intended to improve management of hypotension in aSAH patients. According to the filing, the company received a CRL from the FDA for GTx-104 and is working toward resubmission of a new drug application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. The company disclosed that its current contract manufacturer must remediate cGMP inspection deficiencies cited in the CRL and that "the FDA will not approve the NDA while the facility remains in an unacceptable compliance status." A second, U.S.-based contract manufacturer is also being prepared, but the filing notes this process requires technology transfer, three registration batches, 12 months of stability data, and a successful pre-approval inspection before it can support approval.

The filing also notes that resubmission is expected to require additional non-clinical toxicology studies, and that additional capital may be needed to fund the activities necessary to resubmit the NDA and support FDA review. The company stated plans to potentially license or sell its de-prioritized candidates, GTx-102 and GTx-101. The filing contains forward-looking statements that are the company's own and are subject to its cautionary language regarding known and unknown risks and uncertainties.

What Was Disclosed

Grace Therapeutics filed a Form 10-Q for the quarter ended September 30, 2026, reporting 21,035,930 shares outstanding as of November 11, 2026, and disclosing ongoing regulatory and manufacturing challenges associated with its lead drug candidate, GTx-104.